Compugen Ltd. (TLV: CGEN)

Market Cap	499.50M
Revenue (ttm)	222.49M
Net Income (ttm)	5.94M
Shares Out	n/a
EPS (ttm)	0.07
PE Ratio	84.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,913
Open	572.10
Previous Close	572.10
Day's Range	540.80 - 572.10
52-Week Range	512.00 - 1,175.00
Beta	2.64
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 4, 2025

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 68
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: CGEN

Financial Performance

In 2023, Compugen's revenue was $33.46 million, an increase of 346.12% compared to the previous year's $7.50 million. Losses were -$18.75 million, -44.34% less than in 2022.

Financial numbers in USD